WallStSmart

Merck & Company Inc (MRK)vsZimmer Biomet Holdings Inc (ZBH)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 682% more annual revenue ($65.77B vs $8.41B). MRK leads profitability with a 13.6% profit margin vs 9.1%. ZBH appears more attractively valued with a PEG of 0.63. ZBH earns a higher WallStSmart Score of 69/100 (B-).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

ZBH

Strong Buy

69

out of 100

Grade: B-

Growth: 7.3Profit: 6.0Value: 7.3Quality: 6.5
Piotroski: 3/9Altman Z: 2.09
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued
ZBHUndervalued (+20.4%)

Margin of Safety

+20.4%

Fair Value

$120.04

Current Price

$87.33

$32.71 discount

UndervaluedFair: $120.04Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

ZBH3 strengths · Avg: 8.7/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

PEG RatioValuation
0.638/10

Growing faster than its price suggests

EPS GrowthGrowth
34.1%8/10

Earnings expanding 34.1% YoY

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

ZBH2 concerns · Avg: 3.0/10
Return on EquityProfitability
5.2%3/10

ROE of 5.2% — below average capital efficiency

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : ZBH

The strongest argument for ZBH centers on Price/Book, PEG Ratio, EPS Growth. PEG of 0.63 suggests the stock is reasonably priced for its growth.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : ZBH

The primary concerns for ZBH are Return on Equity, Piotroski F-Score.

Key Dynamics to Monitor

ZBH carries more volatility with a beta of 0.47 — expect wider price swings.

ZBH is growing revenue faster at 9.3% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZBH scores higher overall (69/100 vs 50/100). Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Zimmer Biomet Holdings Inc

HEALTHCARE · MEDICAL DEVICES · USA

Zimmer Biomet is a publicly traded medical device company. The company is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.

Visit Website →

Want to dig deeper into these stocks?